SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Leads Biolabs Doses First Patient in LBL-047 Lupus Trial

Leads Biolabs announced the first patient has been dosed in the Phase I Part B trial of LBL-047 for systemic lupus erythematosus.

9887

Related stories